PMID: 26370095
Question: Are financial incentives cost-effective to support smoking cessation during pregnancy?
Correct Answer: yes

======================= Launch the MCC process =======================
PMID: 26370095
Question: Are financial incentives cost-effective to support smoking cessation during pregnancy?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
The core question is whether financial incentives are cost-effective in supporting smoking cessation during pregnancy. Key information to identify in the abstract includes the cost per quitter, cost per quality-adjusted life year (QALY), comparison to standard cost-effectiveness thresholds, and the reliability and relevance of the provided economic analysis.

**2. Evidence Evaluation**
The study conducted a cost-utility analysis alongside a Phase II randomized controlled trial involving 612 pregnant women in Glasgow, Scotland. The findings indicate an incremental cost of £482 per QALY gained, which is significantly below the commonly accepted threshold of £30,000 per QALY. Additionally, the incremental cost per quitter was £1127, aligning closely with established benchmarks. Although there is some uncertainty highlighted in the probabilistic sensitivity analysis, especially concerning relapse rates after birth, the overall evidence from a robust RCT and the NHS perspective supports the cost-effectiveness of financial incentives for smoking cessation during pregnancy.

**3. Conclusion**
Based on the provided evidence, financial incentives for smoking cessation in pregnancy are cost-effective, as the incremental cost per QALY is well below accepted thresholds. Despite some uncertainties, the strength and relevance of the data substantiate the cost-effectiveness claim.

**4. Final Answer:**
**"yes"**

GPT selected: yes

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether financial incentives (up to £400) for smoking cessation during pregnancy are cost-effective compared to usual care. Key information to evaluate includes the incremental cost-effectiveness ratio (ICER), confidence intervals, and whether the results meet standard cost-effectiveness thresholds (e.g., ≤ £20,000–30,000/QALY in the UK).  

**2. Evidence Evaluation**  
- The study reports an ICER of £482 per QALY gained from a lifetime Markov model, which is well below the UK’s typical threshold of £20,000–30,000/QALY.  
- The 95% confidence interval for the incremental cost was -£93 to £107, and the QALY gain was -0.058 to 0.145, indicating uncertainty but central estimates favor cost-effectiveness.  
- The abstract explicitly states that financial incentives are "highly cost-effective," aligning with the ICER result. However, probabilistic sensitivity analysis highlights uncertainty around relapse post-birth and the expected value of perfect information (£30 million), suggesting further research could refine conclusions.  

**3. Conclusion**  
The ICER of £482/QALY is far below the UK’s cost-effectiveness threshold, strongly supporting cost-effectiveness. While uncertainty exists (e.g., relapse rates), the primary analysis and authors’ conclusion confirm the intervention meets cost-effectiveness criteria. Thus, the answer is **yes**.  

**4. Final Answer:**  
**My final choice is: "yes"**
Qwen selected: yes

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether financial incentives are cost-effective for smoking cessation during pregnancy. Key information to evaluate includes incremental cost per quality-adjusted life year (QALY), comparison to decision thresholds, and evidence of uncertainty in results.

**2. Evidence Evaluation**  
- The study reports an incremental cost-effectiveness ratio (ICER) of **£482/QALY**, far below the UK's typical cost-effectiveness threshold of £20,000–£30,000/QALY.  
- The lifetime model shows **£17 incremental cost** and **0.04 QALY gain**, with probabilistic sensitivity analysis highlighting uncertainty (e.g., relapse post-birth).  
- The abstract explicitly states incentives are "highly cost-effective," aligning with ICER values. However, the confidence intervals for QALY gain (-0.058 to 0.145) and costs (-£93 to £107) indicate statistical uncertainty.  

**3. Conclusion**  
Despite uncertainty, the primary analysis strongly supports cost-effectiveness, as the ICER is well below accepted thresholds. The abstract's conclusion and data justify a "yes," though the uncertainty noted might suggest caution.  

**4. Final Answer**  
**My final choice is: yes**
DeepSeek selected: yes

Consensus reached: All models selected yes